– USA, CA – Claritas Pharmaceuticals, Inc. (TSX: KLY | OTC: KALTF) today announced the appointment of its President and CEO, Bob Farrell, J.D., as Chairman of the board of directors, effective immediately.
The Company also announced the resignations of current independent board members Rob Hutchison and Ronald Erickson, effective immediately. The resignations of Mr. Hutchison and Mr. Erickson follow the recent appointment of Professor Salvatore Cuzzocrea to the Board of Directors.
“I want to extend my gratitude to Rob Hutchison and Ron Erickson for their distinguished service and contributions to our Board of Directors,” said Mr. Farrell. “Both Rob and Ron have been integral members of our Board of Directors, and we wish them all the best going forward.”
“We are assembling a world-class team of experts in the science and clinical use of nitric oxide, at management, advisory, and board levels within the Company,” added Farrell. “We recently announced the addition of Prof. Salvatore Cuzzocrea to our board of directors and the addition of Dr. Garry Southan to our Scientific Advisory Board. Prof. Cuzzocrea and Dr. Southan are world-renowned experts in the science of nitric oxide. Our proprietary new drug, R-107, is a liquid, nitric oxide-releasing molecule that could transform nitric oxide therapy from a difficult to use inhalational therapy to a pharmaceutical that can be administered orally by capsule or by injection. R-107 is a platform technology that is designed to unleash the potential of nitric oxide as a practical out-patient therapy for many diseases and disorders. With R-107, we will position Claritas as the world’s leader in nitric oxide pharmacology.”
About Claritas Pharmaceuticals
Claritas Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for patients with significant unmet medical needs. Claritas focuses on areas of unmet medical need and leverages its expertise to find solutions that will improve health outcomes and dramatically improve people’s lives.
For more information: https://claritaspharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.